Nanoengineered Red Blood Cells Loaded with TMPRSS2 and Cathepsin L Inhibitors Block SARS‐CoV‐2 Pseudovirus Entry into Lung ACE2 + Cells
Advanced Materials · 2024
DOI: 10.1002/adma.202310306 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2024. Verfasst von Hui Yang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Stem Cell and Regenerative Medicine Lab, Beijing Institute of Radiation Medicine, Beijing, 100850, China. Hauptthemen laut MEDLINE: Cathepsin L, COVID-19, SARS-CoV-2, Serine Proteinase Inhibitors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Beijing Institute of Radiation Medicine, National Key Research and Development Program of China.
Abstract (Originalsprache)
The enzymatic activities of Furin, Transmembrane serine proteinase 2 (TMPRSS2), Cathepsin L (CTSL), and Angiotensin‐converting enzyme 2 (ACE2) receptor binding are necessary for the entry of coronaviruses into host cells. Precise inhibition of these key proteases in ACE2 + lung cells during a viral infection cycle shall prevent viral Spike (S) protein activation and its fusion with a host cell membrane, consequently averting virus entry to the cells. In this study, dual‐drug‐combined (TMPRSS2 inhibitor Camostat and CTSL inhibitor E‐64d) nanocarriers (NCs) are constructed conjugated with an anti‐human ACE2 (hACE2) antibody and employ Red Blood Cell (RBC)‐hitchhiking, termed “Nanoengineered RBCs,” for targeting lung cells. The significant therapeutic efficacy of the dual‐drug‐loaded nanoengineered RBCs in pseudovirus‐infected K18‐hACE2 transgenic mice is reported. Notably, the modular nanoengineered RBCs (anti‐receptor antibody+NCs+RBCs) precisely target key proteases of host cells in the lungs to block the entry of Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), regardless of virus variations. These findings are anticipated to benefit the development of a series of novel and safe host‐cell‐protecting antiviral therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Stem Cell and Regenerative Medicine Lab, Beijing Institute of Radiation Medicine, Beijing, 100850, China.
- Department of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing, 100850, China.
- Institute of Health Service and Transfusion Medicine, Beijing, 100850, China.
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.
ORCID-Profile: Jun-Nian Zhou, Xue-Tao Pei, Wen Yue
Förderung
- Beijing Institute of Radiation Medicine
- National Key Research and Development Program of China
Zitieren
APA
Yang, H., Zhou, J. N., Zhang, X. M., Ling, D. D., Sun, Y. B., Li, C. Y., Zhou, Q. Q., Shi, G. N., Wang, S. H., Lin, X. S., Fan, T., Wang, H. Y., Zeng, Q., Jia, Y. L., Xi, J. F., Jin, Y. G., Pei, X. T., & Yue, W. (2024). Nanoengineered Red Blood Cells Loaded with TMPRSS2 and Cathepsin L Inhibitors Block SARS‐CoV‐2 Pseudovirus Entry into Lung ACE2 + Cells. Advanced Materials. https://doi.org/10.1002/adma.202310306
Vancouver
Yang H, Zhou JN, Zhang XM, Ling DD, Sun YB, Li CY, et al. Nanoengineered Red Blood Cells Loaded with TMPRSS2 and Cathepsin L Inhibitors Block SARS‐CoV‐2 Pseudovirus Entry into Lung ACE2 + Cells. Advanced Materials. 2024. doi:10.1002/adma.202310306
BibTeX
@article{Yang2024,
author = {Yang, Hui and Zhou, Jun-Nian and Zhang, Xue-Mei and Ling, Dan-Dan and Sun, Ying-Bao and Li, Chen-Yan and Zhou, Qian-Qian and Shi, Gao-Na and Wang, Si-Han and Lin, Xiao-Song and Fan, Tao and Wang, Hai-Yang and Zeng, Quan and Jia, Ya-Li and Xi, Jia-Fei and Jin, Yi-Guang and Pei, Xue-Tao and Yue, Wen},
title = {Nanoengineered Red Blood Cells Loaded with TMPRSS2 and Cathepsin L Inhibitors Block SARS‐CoV‐2 Pseudovirus Entry into Lung ACE2 + Cells},
journal = {Advanced Materials},
year = {2024},
doi = {10.1002/adma.202310306}
}
EUVIMED